Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

CARTITUDE-1, a phase Ib/II study evaluating the safety and efficacy of ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory multiple myeloma, yielded early, deep, and durable responses at 12 months. Here, we present updated results 2 years after last patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Thomas, Usmani, Saad Z., Berdeja, Jesus G., Agha, Mounzer, Cohen, Adam D., Hari, Parameswaran, Avigan, David, Deol, Abhinav, Htut, Myo, Lesokhin, Alexander, Munshi, Nikhil C., O'Donnell, Elizabeth, Stewart, A. Keith, Schecter, Jordan M., Goldberg, Jenna D., Jackson, Carolyn C., Yeh, Tzu-Min, Banerjee, Arnob, Allred, Alicia, Zudaire, Enrique, Deraedt, William, Olyslager, Yunsi, Zhou, Changwei, Pacaud, Lida, Madduri, Deepu, Jakubowiak, Andrzej, Lin, Yi, Jagannath, Sundar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937098/
https://www.ncbi.nlm.nih.gov/pubmed/35658469
http://dx.doi.org/10.1200/JCO.22.00842

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937098/
https://www.ncbi.nlm.nih.gov/pubmed/35658469
http://dx.doi.org/10.1200/JCO.22.00842

Ejemplares similares